Metabasis Therapeutics, Inc. (NASDAQ: MBRX), a biopharmaceutical company, focuses their efforts on discovering, developing and commercializing innovative drugs by applying its scientific expertise, proprietary technologies and unique capabilities for targeting the liver and liver pathways. The company has established advanced research programs and a broad pipeline of product candidates, all of which were developed through the leveraging of their proprietary technologies. For further information, visit the Company’s web site at www.mbasis.com.
- 17 years ago
QualityStocks
Metabasis Therapeutics, Inc. (NASDAQ: MBRX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Expands Sports.com Brand with NBA Yearbook Campaign Covering Seven Iconic Franchises
SEGG Media (NASDAQ: SEGG, LTRYW), parent company of Sports.com, announced a major step in its…
-
ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Completes Montauban Mill Building Construction; Transitions to Equipment Sourcing, Delivery, and Installation
This article has been disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and…
-
Strawberry Fields REIT Inc. (NYSE American: STRW) Announces Q3 2025 Financial Results, Holds Quarterly Earnings Call
Strawberry Fields REIT announced financial results for the quarter ending September 30th 2025, and also…